Clinical Trial Update: Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update reports on selinexor for relapsed small cell lung cancer; the study was terminated and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• XPOVIO (selinexor) (selinexor)

Snippet

Sponsor: Erin Bertino | Conditions: Recurrent Small Cell Lung Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2016-05-16